- Home
- FLGT vs MGTX Comparison
FLGT vs MGTX Comparison
Compare FLGT & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLGT
- MGTX
- Stock Information
- Founded
- FLGT 2011
- MGTX 2015
- Country
- FLGT United States
- MGTX United States
- Employees
- FLGT N/A
- MGTX N/A
- Industry
- FLGT Medical Specialities
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FLGT Health Care
- MGTX Health Care
- Exchange
- FLGT Nasdaq
- MGTX Nasdaq
- Market Cap
- FLGT 588.5M
- MGTX 520.8M
- IPO Year
- FLGT 2016
- MGTX N/A
- Fundamental
- Price
- FLGT $19.37
- MGTX $8.47
- Analyst Decision
- FLGT Buy
- MGTX Strong Buy
- Analyst Count
- FLGT 2
- MGTX 2
- Target Price
- FLGT $24.00
- MGTX $24.00
- AVG Volume (30 Days)
- FLGT 206.2K
- MGTX 541.8K
- Earning Date
- FLGT 08-01-2025
- MGTX 08-11-2025
- Dividend Yield
- FLGT N/A
- MGTX N/A
- EPS Growth
- FLGT N/A
- MGTX N/A
- EPS
- FLGT N/A
- MGTX N/A
- Revenue
- FLGT $292,448,000.00
- MGTX $34,508,000.00
- Revenue This Year
- FLGT $11.79
- MGTX $365.04
- Revenue Next Year
- FLGT $10.45
- MGTX $73.18
- P/E Ratio
- FLGT N/A
- MGTX N/A
- Revenue Growth
- FLGT 1.71
- MGTX 203.23
- 52 Week Low
- FLGT $14.57
- MGTX $3.85
- 52 Week High
- FLGT $25.11
- MGTX $8.75
- Technical
- Relative Strength Index (RSI)
- FLGT 41.40
- MGTX 76.43
- Support Level
- FLGT $19.18
- MGTX $6.31
- Resistance Level
- FLGT $19.96
- MGTX $8.75
- Average True Range (ATR)
- FLGT 0.50
- MGTX 0.45
- MACD
- FLGT -0.07
- MGTX 0.19
- Stochastic Oscillator
- FLGT 26.29
- MGTX 89.55
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.